Publication: Riesgo cardiovascular en relación a los AINEs.
Loading...
Official URL
Full text at PDC
Publication Date
2015-02
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Citations
Exportar
Abstract
Se pretende el estudio del riesgo asociado al uso de AINEs en cuanto a problemas cardiovasculares, y su importancia en terapéutica, mediante revisión bibliográfica de estudios realizados por la comunidad científica.
El punto clave de partida fueron las alertas y notificaciones consecutivas en los años por parte de la AEMPS y de la EMA, concluyendo con restricciones específicas para ciertos fármacos. Haciéndose relevante y necesario la realización de nuevos estudios científicos para profundizar en estos indicios.
Tras la evaluación de los estudios, se concluye que el ibuprofeno no tiene un aumento de riesgo significativo a las dosis recomendadas, pero con dosis superiores lleva un claro aumento del riesgo de ictus e infarto de miocardio, teniendo un riesgo global mayor que otros AINEs, pero menor que los coxibs.
Por otro lado, el naproxeno fue el único que demostró una disminución en el riesgo, por disminución de los procesos trombóticos.
Así mismo, el diclofenaco presenta un riesgo similar al de los coxibs, siendo este ligeramente mayor al del resto de AINEs estudiados. No hay una dosis límite establecida como segura.
Finalmente, el riesgo es evidente cuando se habla de uso de coxibs, estando contraindicado en pacientes con eventos cardiovasculares previos.
En la actualidad sigue siendo un estudio activo, en continua reevaluación.
This study analyzes the risk associated with the use of NSAIDs, in terms of cardiovascular problems, and its importance in the therapeutic aims, through literature review of studies by the scientific community. The main starting point was alerts and notifications by the AEMPS and the EMA, concluding with specific restrictions for certain drugs. Becoming relevant and necessary to conduct further scientific studies to deepen these signs. After evaluation of the studies concluded that ibuprofen has no significantly increased risk at recommended doses, but at higher doses takes a clear increased risk of stroke and myocardial infarction, with an overall higher risk than other NSAIDs, but less than coxibs. Moreover, the naproxen was the only one that demonstrated decreased risk by decreasing the thrombotic processes. Likewise, diclofenac has a similar risk as coxibs do and slightly higher than the other NSAID studied. There is no safe limit dose established. Finally, the risk is obvious when it comes to use of coxibs and is contraindicated in patients with previous cardiovascular events. Today remains an active study, with continuous reassessment.
This study analyzes the risk associated with the use of NSAIDs, in terms of cardiovascular problems, and its importance in the therapeutic aims, through literature review of studies by the scientific community. The main starting point was alerts and notifications by the AEMPS and the EMA, concluding with specific restrictions for certain drugs. Becoming relevant and necessary to conduct further scientific studies to deepen these signs. After evaluation of the studies concluded that ibuprofen has no significantly increased risk at recommended doses, but at higher doses takes a clear increased risk of stroke and myocardial infarction, with an overall higher risk than other NSAIDs, but less than coxibs. Moreover, the naproxen was the only one that demonstrated decreased risk by decreasing the thrombotic processes. Likewise, diclofenac has a similar risk as coxibs do and slightly higher than the other NSAID studied. There is no safe limit dose established. Finally, the risk is obvious when it comes to use of coxibs and is contraindicated in patients with previous cardiovascular events. Today remains an active study, with continuous reassessment.